Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company focused on central nervous system (CNS) and immunology treatments, announced that its management team will participate in two upcoming investor conferences in May 2026. The company will present at the RBC Capital Markets Global Healthcare Conference on May 19 in New York and at A.G.P.'s Annual Virtual Healthcare Conference on May 20. These appearances provide an opportunity for Tonix to showcase its commercial portfolio and clinical pipeline to the investment community.
The company's recently approved flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), represents the first new treatment for fibromyalgia in over 15 years. Tonix's CNS commercial infrastructure also supports its marketed acute migraine products, Zembrace® SymTouch® and Tosymra®. Beyond commercial products, the company is advancing TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, Tonix's CNS pipeline includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease.
In the immunology space, Tonix is advancing monoclonal antibodies including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs address areas of high unmet medical need. The company emphasizes that its product development candidates are investigational new drugs or biologics whose efficacy and safety have not been established and have not been approved for any indication.
Investors can access the full press release and stay updated on Tonix news through the company's newsroom at https://ibn.fm/TNXP. The announcements regarding the conferences underscore Tonix's commitment to engaging with the financial community and highlighting its progress across CNS and immunology therapeutic areas.
Tonix Pharmaceuticals is a fully integrated commercial-stage biotechnology company dedicated to developing treatments for CNS and immunology conditions with high unmet medical need. The company's commercial infrastructure supports its marketed products and pipeline candidates, aiming to bring innovative therapies to patients. Further details about Tonix and its programs can be found at the company's website or through the InvestorWire platform at https://www.InvestorWire.com.
